0

Atreleuton

INQUIRY Add to cart
For Research Use Only | Not For Clinical Use
CATAP154355767
CAS154355-76-7
Structure
Molecular Weight318.37
Description≥98% (HPLC)
SolubilityDMSO: 10 mg/mL, clear
Assay≥98% (HPLC)
Colorwhite to beige
Formpowder
Size5MG, 25MG
Storage Conditions2-8°C
1

5-Lipoxygenase as a Drug Target: A Review on Trends in Inhibitors Structural Design, SAR and Mechanism Based Approach

Shweta Sinha, Mukesh Doble, S L Manju

Bioorg Med Chem. 2019 Sep 1;27(17):3745-3759.

PMID: 31331653

1

Effect of 5-lipoxygenase Inhibitor, VIA-2291 (Atreleuton), on Epicardial Fat Volume in Patients With Recent Acute Coronary Syndrome

Shone O Almeida, Reuben J Ram, April Kinninger, Matthew J Budoff

J Cardiovasc Comput Tomogr. 2020 Jan 17;S1934-5925(19)30210-2.

PMID: 31983575

1

Effect of Treatment With 5-lipoxygenase Inhibitor VIA-2291 (Atreleuton) on Coronary Plaque Progression: A Serial CT Angiography Study

Suguru Matsumoto, Reda Ibrahim, Jean C Grégoire, Philippe L L'Allier, Josephine Pressacco, Jean-Claude Tardif, Matthew J Budoff

Clin Cardiol. 2017 Apr;40(4):210-215.

PMID: 27883201

1

Treatment With 5-lipoxygenase Inhibitor VIA-2291 (Atreleuton) in Patients With Recent Acute Coronary Syndrome

Jean-Claude Tardif, Philippe L L'allier, Reda Ibrahim, Jean C Grégoire, Anna Nozza, Mariève Cossette, Simon Kouz, Marc-André Lavoie, Janie Paquin, Tilmann M Brotz, Rebecca Taub, Josephine Pressacco

Circ Cardiovasc Imaging. 2010 May;3(3):298-307.

PMID: 20190281

  • Verification code
Contact Us

Send Us a Request

What is your specific need? We will do everything we can to meet your expectations.
Online Inquiry

Online Inquiry

For any inquiry, question or recommendation, please call: or fill out the following form.

  • Verification code

Head Office

  • Tel:
  • Email:

Follow us on

qrcode